Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Centrinone-B (LCR-323) is a potent and highly selective inhibitor of PLK4 (Ki: 0.59 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 689.00 | |
50 mg | 6-8 weeks | $ 896.00 | |
100 mg | 6-8 weeks | $ 1,340.00 |
Description | Centrinone-B (LCR-323) is a potent and highly selective inhibitor of PLK4 (Ki: 0.59 nM). |
Targets&IC50 | Aurora A:1239 nM (ki), Aurora B:5597.14 nM (ki), PLK4 (G95L):497.53 nM (ki), PLK4:0.59 nM (ki) |
In vitro | Centrinone-B (0-200 nM) significantly decreases cell viability of PLK4-centriole conjunction melanoma cell lines except for p53 mutant SK-MEL-28, and this effect is via inhibition of PLK4. Centrinone-B slightly binds to Aurora A and Aurora B (Kis: 1239 nM and 5597.14 nM). Centrinone-B exhibits >1000-fold selectivity for Plk4 over Aurora A/B in vitro and does not affect cellular Aurora A or B substrate phosphorylation at concentrations that deplete centrosomes [1]. Inhibition of PLK4 by Centrinone-B also induces apoptosis in human melanoma cell lines [2]. |
Synonyms | LCR-323 |
Molecular Weight | 631.67 |
Formula | C27H27F2N7O5S2 |
CAS No. | 1798871-31-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (39.58 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Centrinone-B 1798871-31-4 Cell Cycle/Checkpoint Chromatin/Epigenetic Aurora Kinase LCR-323 Centrinone B LCR323 LCR 323 CentrinoneB inhibitor inhibit